Perry has served as audit committee chair at Merus N.V. since 2016. He served as chief financial and administrative officer at Aegerion Pharmaceuticals Inc. from 2015 until the company's merger with Novelion Therapeutics Inc., after which he served as chief financial and administrative officer at Novelion until 2017.
Prior to joining Aegerion, Perry held the role of chief financial and business officer at Eleven Biotherapeutics, Inc. from 2014-2015. He was a member of the board of directors, audit committee chair and compensation committee member at Ocata Therapeutics, Inc. from 2011 until the company was acquired by Astellas Pharma Inc. in 2016.
Perry holds a Bachelor of Arts Degree in Economics and Political Science from Amherst College.
Kala is focused on the development and commercialisation of therapeutics using its proprietary mucus-penetrating particle (MMP) technology, with an initial focus on the treatment of eye diseases.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer